These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22463610)

  • 1. CB1 receptor antagonists: new discoveries leading to new perspectives.
    Kirilly E; Gonda X; Bagdy G
    Acta Physiol (Oxf); 2012 May; 205(1):41-60. PubMed ID: 22463610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists.
    Lazary J; Juhasz G; Hunyady L; Bagdy G
    Trends Pharmacol Sci; 2011 May; 32(5):270-80. PubMed ID: 21497918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
    Moreira FA; Grieb M; Lutz B
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):133-44. PubMed ID: 19285266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
    Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
    Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
    Christopoulou FD; Kiortsis DN
    J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents.
    Sharma MK; Murumkar PR; Barmade MA; Giridhar R; Yadav MR
    Expert Opin Ther Pat; 2015; 25(10):1093-116. PubMed ID: 26161824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
    Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
    Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents.
    Lee HK; Choi EB; Pak CS
    Curr Top Med Chem; 2009; 9(6):482-503. PubMed ID: 19689362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 14. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
    Zieba R
    Postepy Hig Med Dosw (Online); 2007 Oct; 61():612-26. PubMed ID: 17971763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
    Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A
    Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
    Silvestri C; Di Marzo V
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The psychiatric side-effects of rimonabant.
    Moreira FA; Crippa JA
    Braz J Psychiatry; 2009 Jun; 31(2):145-53. PubMed ID: 19578688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
    Janero DR; Makriyannis A
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).
    Raffa RB; Ward SJ
    J Clin Pharm Ther; 2012 Jun; 37(3):260-5. PubMed ID: 21740450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.